In this population of patients initiating disease-modifying drug (DMD) treatment within 2 years of multiple sclerosis (MS) diagnosis, mean time to first DMD was 112.6 days, a recent study found. Identifying factors associated with delayed treatment may provide better understanding of the reasons for delay, leading to improved disease management. This retrospective cohort study included newly diagnosed patients with MS from a US administrative claims database, aged 18–65 years, with a first MS diagnosis between January 1, 2007, and June 30, 2013. Researchers found:
- 37.4% of patients initiated DMD treatment within 2 years of MS diagnosis and were included in the primary analysis (n= 7,124).
- Mean (standard deviation [SD]) time from MS diagnosis to first DMD was 112.6 (148.3) days (median=51); 30.7% received first DMD in <30 days, 55.1% in <60 days, and 18.5% not until ≥180 days after diagnosis.
- Logistic regression found that younger age; not living in the Northeast; diagnoses of balance disorders, numbness, and optical neuritis; the absence of musculoskeletal diagnoses; and a neurologist visit or MRI within 90 days before diagnosis were associated with DMD initiation within 60 days.
Edwards NC, Munsell M, Menzin J, Phillips AL. Factors associated with early initiation of disease-modifying drug treatment in newly diagnosed patients with multiple sclerosis. [Published online ahead of print March 1, 2018]. Curr Med Res Opin. doi:10.1080/03007995.2018.1447452.
This Week's Must Reads
Vegetable/Fruit Intake Benefits Cognitive Function, Neurology; ePub 2018 Nov 21; Yuan, Fondell, et al
Alzheimer Dementia and Age-Related Neuropathologies, Ann Neurol; ePub 2018 Nov 12; Boyle, Yu, et al
Kidney Function and Post-Stroke Mortality Examined, Stroke; ePub 2018 Nov 9; El Husseini, Fonarow, et al
Meditation May Help to Alleviate US Stroke Burden, J Stroke Cerebrovasc Dis; ePub 2018 Nov 24; Ambavane, et al
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
Must Reads in Multiple Sclerosis
Exposure to Animals Associated with Risk of MS, Mult Scler Relat Disord; ePub 2018 Nov 15; de Jong, et al
White Matter Tract Disruption, Fatigue Examined, Mult Scler Relat Disord; ePub 2018 Nov 9; Fuchs, et al
Coexistence of Multiple Sclerosis, Alzheimer Disease, Mult Scler Relat Disord; ePub 2018 Oct 27; Luczynski, et al
Body Mass Index Linked with Brain Volume Change, Neurology; ePub 2018 Nov 14; Mowry, Azevedo, et al
Detection of Whole Brain, Deep GM Atrophy in MS, PLoS One; ePub 2018 Nov 8; Chu, Kim, et al